id3753.html
In development: Guidance, quality standards and advice
Thu, 13 Feb 2025 05:55:00 GMT
Tislelizumab in combination for untreated advanced non-small-cell lung cancer ID6162 Technology appraisal guidance TBC Tisotumab vedotin for treating recurrent or metastatic cervical cancer after ...